Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016;2:15088. https://doi.org/10.1038/nrdp.2015.88.

Article  PubMed  Google Scholar 

Dierickx D, Habermann TM. Post-Transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378:549–62. https://doi.org/10.1056/NEJMra1702693.

Article  PubMed  CAS  Google Scholar 

Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transpl. 2013;13:41–54. https://doi.org/10.1111/ajt.12004. quiz 54.

Article  CAS  Google Scholar 

Romero S, Montoro J, Guinot M, Almenar L, Andreu R, Balaguer A, et al. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leuk Lymphoma. 2019;60:142–50. https://doi.org/10.1080/10428194.2018.1474462.

Article  PubMed  Google Scholar 

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. https://doi.org/10.1182/blood-2016-01-643569.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48. https://doi.org/10.1038/s41375-022-01620-2.

Article  PubMed  PubMed Central  Google Scholar 

Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transpl. 2004;4:222–30. https://doi.org/10.1046/j.1600-6143.2003.00325.x.

Article  Google Scholar 

Dierickx D, Tousseyn T, Sagaert X, Fieuws S, Wlodarska I, Morscio J, et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma. 2013;54:2433–40. https://doi.org/10.3109/10428194.2013.780655.

Article  PubMed  Google Scholar 

Dharnidharka VR, Ruzinova MB, Marks LJ. Post-Transplant lymphoproliferative disorders. Semin Nephrol. 2024;44:151503. https://doi.org/10.1016/j.semnephrol.2024.151503.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dierickx D, Tousseyn T, Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood. 2015;126:2274–83. https://doi.org/10.1182/blood-2015-05-615872.

Article  PubMed  CAS  Google Scholar 

DeStefano CB, Desai SH, Shenoy AG, Catlett JP. Management of post-transplant lymphoproliferative disorders. Br J Haematol. 2018;182:330–43. https://doi.org/10.1111/bjh.15263.

Article  PubMed  Google Scholar 

Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A Multi-Institutional study. Blood. 1999;94:2208–16. https://doi.org/10.1182/blood.V94.7.2208.419k21_2208_2216.

Article  PubMed  CAS  Google Scholar 

Landgren O, Gilbert ES, Rizzo JD, Socié G, Banks PM, Sobocinski KA, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992–5001. https://doi.org/10.1182/blood-2008-09-178046.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Clerico M, Dogliotti I, Aroldi A, Consoli C, Giaccone L, Bruno B, et al. Post-Transplant lymphoproliferative disease (PTLD) after allogeneic hematopoietic stem cell transplantation: biology and treatment options. J Clin Med. 2022;11:7542. https://doi.org/10.3390/jcm11247542.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Arai Y, Yamashita K, Mizugishi K, Kondo T, Kitano T, Hishizawa M, et al. Risk factors for hypogammaglobulinemia after allo-SCT. Bone Marrow Transpl. 2014;49:859–61. https://doi.org/10.1038/bmt.2014.28.

Article  CAS  Google Scholar 

Luterbacher F, Bernard F, Baleydier F, Ranza E, Jandus P, Blanchard-Rohner G. Case report: persistent hypogammaglobulinemia more than 10 years after rituximab given Post-HSCT. Front Immunol. 2021;12:773853. https://doi.org/10.3389/fimmu.2021.773853.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ogonek J, Kralj Juric M, Ghimire S, Varanasi PR, Holler E, Greinix H, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:507. https://doi.org/10.3389/fimmu.2016.00507.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Trofe J, Buell JF, Beebe TM, Hanaway MJ, First MR, Alloway RR, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn international transplant tumor registry experience. Am J Transpl. 2005;5:775–80. https://doi.org/10.1111/j.1600-6143.2005.00776.x.

Article  Google Scholar 

Caillard S, Lelong C, Pessione F, Moulin B, French PTLD, Working Group. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am J Transpl. 2006;6:2735–42. https://doi.org/10.1111/j.1600-6143.2006.01540.x.

Article  CAS  Google Scholar 

Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol. 2009;24:731–6. https://doi.org/10.1007/s00467-007-0582-3.

Article  PubMed  Google Scholar 

MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology. 2011;140:1768–75. https://doi.org/10.1053/j.gastro.2011.02.047.

Article  PubMed  CAS  Google Scholar 

Reiche W, Tauseef A, Sabri A, Mirza M, Cantu D, Silberstein P, et al. Gastrointestinal manifestations, risk factors, and management in patients with post-transplant lymphoproliferative disorder: A systematic review. World J Transpl. 2022;12(8):268–80.

Article  Google Scholar 

Shah N, Eyre TA, Tucker D, Kassam S, Parmar J, Featherstone C, et al. Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients - A British society for haematology guideline. Br J Haematol. 2021;193:727–40. https://doi.org/10.1111/bjh.17421.

Article  PubMed  Google Scholar 

Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Váry M, Babel N, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transpl. 2005;5:2901–6. https://doi.org/10.1111/j.1600-6143.2005.01098.x.

Article  CAS  Google Scholar 

Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa AM, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107:3053–7. https://doi.org/10.1182/blood-2005-01-0377.

Article  PubMed  CAS  Google Scholar 

Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica. 2007;92:1489–94. https://doi.org/10.3324/haematol.11360.

Article  PubMed  CAS  Google Scholar 

Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13:196–206. https://doi.org/10.1016/S1470-2045(11)70300-X.

Article  PubMed  CAS  Google Scholar 

Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, et al. Response to rituximab induction is a predictive marker in B-Cell Post-Transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an International, Prospective, multicenter phase II trial. J Clin Oncol. 2017;35:536–43. https://doi.org/10.1200/JCO.2016.69.3564.

Article  PubMed  CAS  Google Scholar 

Zimmermann H, Koenecke C, Dreyling MH, Pott C, Dührsen U, Hahn D, et al. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial. Leukemia.